# Key Takeaways

* McKesson reported Q4 fiscal 2026 adjusted EPS of $11.69, beating consensus estimates of $11.56 by 1.1%.
* Quarterly revenue reached $96.3 billion, up 6% year-over-year but below expectations of about $101 billion.
* Full-year fiscal 2026 adjusted EPS hit $39.11, up 18% from prior year, surpassing guidance midpoint.
* FY2026 revenue grew 12% to $403.4 billion, driven by oncology and pharmaceutical segments.
* Company issued FY2027 adjusted EPS guidance of $43.80-$44.60, implying 12-14% growth.
* Strong free cash flow of $5.4 billion for FY2026 supported $5.1 billion returned to shareholders.

# Understanding McKesson's Earnings and Their Implications

As a key player in healthcare distribution, [McKesson Corporation (MCK)](https://tickeron.com/ticker/MCK/) is central to the pharmaceutical supply chain, supporting hospitals, pharmacies, and providers as demand grows for specialty drugs and GLP-1 therapies—those glucose-like peptide-1 agonists used for diabetes and weight management. This Q4 fiscal 2026 report, covering the period ended March 31, 2026, wraps up a year of significant transformation, including oncology expansion and portfolio refinement. From what I see, investors are right to focus on execution in high-margin areas like biopharma services, even as challenges like reimbursement pressures and industry consolidation linger. These results highlight McKesson's capacity for operating leverage, which could ripple through to peers and the wider healthcare sector.

# Breaking Down the Reported Numbers

McKesson posted fourth quarter fiscal 2026 revenues of $96.3 billion, marking a 6% rise from $90.8 billion in the year-ago quarter. While this beat last year's figures, it came in below consensus expectations of around $101 billion, largely due to softer results in medical-surgical solutions and generic pricing pressures.

Adjusted earnings per diluted share landed at $11.69, topping the $11.56 consensus and up 16% from $10.12 a year earlier. GAAP EPS was $13.71, versus $10.01 last year. Standout performers included the Oncology & Multispecialty segment, with revenues up 35% to $12.7 billion and operating profit up 53%, alongside North American Pharmaceutical revenues growing 3% to $79.1 billion.

For the full fiscal year 2026, revenues climbed 12% to $403.4 billion, and adjusted EPS reached $39.11, an 18% increase from $33.05, exceeding the company's guidance range of $38.80-$39.20. Cash from operations totaled $6.2 billion, translating to free cash flow of $5.4 billion after capital expenditures. McKesson returned $5.1 billion to shareholders through repurchases and dividends, including a new $2.25 billion accelerated share repurchase.

Looking ahead, fiscal 2027 guidance calls for adjusted EPS of $43.80 to $44.60. The company also reaffirmed its long-term targets of 13%-16% adjusted EPS compound annual growth rate.

# Market Response and What Investors Are Thinking

After the May 7, 2026, release following market close, [MCK](https://tickeron.com/ticker/MCK/) shares opened up about 1.5% at $754.76 on May 8, driven by the EPS beat, full-year outperformance, and solid FY2027 guidance—despite the revenue miss. After-hours trading showed an initial modest gain of 0.85%. Overall sentiment leans positive, supported by robust oncology growth and capital returns, though the revenue shortfall has tempered some excitement amid ongoing sector volatility. I also checked this using [Tickeron’s AI Screener](https://tickeron.com/app-ng/screener/stocks/diy/industries) to gauge how the stock stacks up against industry peers on key metrics.

# Looking Ahead: Outlook and Factors to Watch

The FY2027 adjusted EPS guidance of $43.80-$44.60 points to sustained momentum, implying 12%-14% growth over FY2026's $39.11. This fits with the reaffirmed long-term 13%-16% EPS CAGR, backed by a portfolio honed on high-growth segments.

One thing that stands out is the planned separation of the Medical-Surgical Solutions segment, with initial financing in place—a $1 billion term loan and revolver. This move should sharpen focus on higher-margin oncology (targeting 13%-16% operating profit growth) and biopharma services. Prescription Technology Solutions, aiming for 10%-13% growth, merits attention for its software and analytics role.

Key broader trends to monitor include GLP-1 drug demand, specialty pharma volumes, and North American Pharmaceutical performance (5%-8% operating profit growth target). Risks persist from generic margin pressures, reimbursement shifts, and M&A integration. Strong free cash flow generation, now at $5.4 billion annually, bolsters shareholder returns under the expanded $7.7 billion repurchase authorization.

# Why I Rely on Tickeron’s AI Screener

In my own research and trading, I’ve found [Tickeron’s AI Screener](https://tickeron.com/app-ng/screener/stocks/diy/industries) invaluable as an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of assets using customizable criteria like technical patterns, fundamentals, trends, volatility, and AI signals—covering industry, market cap, indicators, price patterns, and performance metrics. This helps pinpoint trade ideas, breakout candidates, and opportunities far more efficiently than manual methods. If you’re looking to streamline your analysis like I do, it’s worth exploring.

McKesson (MCK) Delivers Strong Q4 EPS Beat and FY2027 Guidance